Amy Liu is a San Francisco-based investor at Mubadala Capital, the US Ventures arm of Mubadala Capital. In her role, she focuses on early and growth stage investments in healthcare and life sciences with a focus on biotechnology companies. Prior to Mubadala, Amy worked at BridgeBio Pharma (NASDAQ: BBIO) across various corporate development, business development and M&A roles. Amy began her career as a Senior Research Data Specialist at the University of Pennsylvania and helped to spearhead the development of the largest natural history registry for Castleman disease. She has also worked as a sell side analyst at Evercore ISI covering small and mid - cap biotech companies on the #1 Institutional Investor ranked team. Amy has published in several high impact journals such Blood and The Lancet Hematology. Amy was a graduate of the Vagelos Life Science and Management Program at the University of Pennsylvania and a recipient of the Vagelos Prize for Achievement in Scientific Research for her work on Castleman disease.
4:15 PM - 5:15 PM (PDT)
Wednesday, June 15
The power of RNA has become more evident during the COVID-19 pandemic. However, stakeholders…